BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bolt Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.04+0.04 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-469.3%+20821.6 pts over 5 years
Net margin
-433.7%+25855.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.1% | +10.3% | +101.6% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 80.5% | -79.7% | |
| Return on assets | – | – | -42.7% | |
| Current ratio | – | 2.25 | 3.59 | |
| Capex to revenue | – | 1412.1% | 0.9% | |
| Diluted shares | – | 0M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bolt Biotherapeutics generated $304.23M from operations and spent $4.61M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$304.23M
Used
$4.61M
Capital expenditure$4.61M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-433.7%
×Asset turnover0.10×
×Equity multiplier1.87×
=Return on equity, FY2025-79.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -433.7% | 0.10× | 1.87× | -79.7% |
| FY2024 | -820.8% | 0.06× | 1.53× | -74.3% |
| FY2023 | -878.6% | 0.04× | 1.36× | -48.7% |
| FY2022 | -1537.8% | 0.02× | 1.27× | -41.8% |
| FY2021 | -7824.7% | 0.01× | 2.44× | -135.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$33.38M
- Cash generatingOperating cash flow above zero-$39.85M
- Return on assets improvedROA up on the prior year-39.5% → -33.5%
- Earnings backed by cashOperating cash flow above net income-$39.85M vs -$33.38M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.20 → 3.59
- No dilutionShare count did not rise2M → 2M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.05 → 0.08